phone

Bacterial Vaginosis - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 48
  • Category: Pharmaceuticals
  • Country: Global
Bacterial Vaginosis - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2017, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis - Overview
Bacterial Vaginosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis - Companies Involved in Therapeutics Development
Evofem Inc
Osel Inc
Starpharma Holdings Ltd
Symbiomix Therapeutics LLC
Bacterial Vaginosis - Drug Profiles
Amphora - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
secnidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
subtilosin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacterial Vaginosis - Dormant Projects
Bacterial Vaginosis - Discontinued Products
Bacterial Vaginosis - Product Development Milestones
Featured News & Press Releases
Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation
Mar 30, 2017: VivaGel BV phase 3 trials for prevention of BV completed
Mar 23, 2017: Symbiomix Therapeutics Announces FDAs Acceptance of New Drug Application for Solosec with Priority Review Status
Feb 22, 2017: Symbiomix Therapeutics Appoints David L. Stern as Chief Executive Officer
Jan 19, 2017: Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec for the Treatment of BV
Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA
Nov 07, 2016: Symbiomix Therapeutics to Present Data on Solosec (Secnidazole) Oral Granules at 2016 AAPS Annual Meeting and Exposition
Oct 25, 2016: Symbiomix Therapeutics Data Presented on Clinician/Patient Perspectives of Bacterial Vaginosis at International Society for Quality of Life Research 23rd Annual Conference
Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program
Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH
Aug 17, 2016: Symbiomix Therapeutics Accelerates Commercial Launch Preparation for Solosec Following Presentation of Results from Second Pivotal Trial at IDSOG
Jul 21, 2016: Osel Comments on New Study Showing Role of Vaginal Microbiome in Women Health
May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing
May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis
Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Bacterial Vaginosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Bacterial Vaginosis - Pipeline by Evofem Inc, H2 2017
Bacterial Vaginosis - Pipeline by Osel Inc, H2 2017
Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H2 2017
Bacterial Vaginosis - Pipeline by Symbiomix Therapeutics LLC, H2 2017
Bacterial Vaginosis - Dormant Projects, H2 2017
Bacterial Vaginosis - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Bacterial Vaginosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Bacterial Vaginosis - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2017, provides an overview of the Bacterial Vaginosis

View Report

Bacterial Pneumonia -Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Bacterial Pneumonia. The key objective of the report is to establish the understanding for all

View Report

Bacterial (Pyogenic) Meningitis -Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Bacterial (Pyogenic) Meningitis. The key objective of the report is to establish the understanding

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports